Loading...
XJPX
6090
Market cap24mUSD
Dec 05, Last price  
655.00JPY
1D
1.71%
1Q
-11.49%
Jan 2017
-58.47%
IPO
-80.42%
Name

Human Metabolome Technologies Inc

Chart & Performance

D1W1MN
XJPX:6090 chart
P/E
15.91
P/S
2.88
EPS
41.18
Div Yield, %
2.29%
Shrs. gr., 5y
Rev. gr., 5y
6.32%
Revenues
1.35b
+3.57%
1,118,495,0001,124,067,0001,223,281,0001,299,225,0001,345,671,000
Net income
243m
-14.88%
-47,794,00058,214,000267,785,000285,758,000243,248,000
CFO
237m
-16.90%
184,075,000-34,171,000324,033,000284,962,000236,795,000
Dividend
Jun 27, 20250 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
IPO date
Dec 24, 2013
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT